Market Cap 308.50M
Revenue (ttm) 236.20M
Net Income (ttm) -5.35M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 43.50
Profit Margin -2.27%
Debt to Equity Ratio 1.79
Volume 1,507,049
Avg Vol 2,898,624
Day's Range N/A - N/A
Shares Out 268.26M
Stochastic %K 13%
Beta 0.35
Analysts Strong Sell
Price Target $4.20

Company Profile

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 617 871 2098
Fax: 617 871 2099
Address:
245 First Street, Suite 1400, Cambridge, United States
GREENJMB81
GREENJMB81 May. 13 at 6:16 PM
0 · Reply
FullTrust
FullTrust May. 13 at 6:08 PM
$AKBA i know your birthday you sent me gift got lost in the mail 🎁 I’ll cut you some slack John
1 · Reply
Coach_B1067
Coach_B1067 May. 13 at 5:52 PM
$AKBA I guess those green bars at the bottom of the chart do not mean anything....smh
1 · Reply
MB76
MB76 May. 13 at 5:51 PM
$AKBA This👇clown thinks any of us “actual” investors in AKBA give a sh*t what he thinks or posts!
1 · Reply
Love_To_Learn
Love_To_Learn May. 13 at 5:47 PM
$AKBA JOHN ILL NEED A FAVOUR SIR * MESSAGING U NOW OFF TOPI NEED U TO DO THIS FOR ME *
0 · Reply
Dipwhits
Dipwhits May. 13 at 5:01 PM
$AKBA As I think back... During my years as a financial analyst and advisor, I would often ask clients a simple question: “What is your most valuable asset?” Almost every answer was material. Money. Homes. Businesses. Portfolios. Very few ever answered: their health or their time. And yet without either of those, none of the material things are even possible. The older I get, the more I realize the market can quietly consume both if you let it. Not just money, but years of your life through stress, waiting, chasing and attachment. Success still matters to me. Ambition still matters. But I think wisdom is learning the difference between building a life and spending your life endlessly waiting for one position, one moment or one number to finally make you feel complete.
2 · Reply
Coach_B1067
Coach_B1067 May. 13 at 5:00 PM
$AKBA No price movement since 10:40?....Seems 'sus'
0 · Reply
The4ccountant
The4ccountant May. 13 at 4:55 PM
$AKBA Nevermind, don’t want it anymore. 💩
0 · Reply
DollaDollaPils
DollaDollaPils May. 13 at 4:32 PM
$AKBA will still be useful for a tax harvest later in the year. Prove me wrong JB and crew, I’d be very happy to be wrong.
0 · Reply
Dipwhits
Dipwhits May. 13 at 4:27 PM
$AKBA One thing this journey has taught me is the market can quietly consume more than money if you let it. It can consume time. And at some point you realize time is the more finite asset. I still believe in the long-term potential here and I’m committed to my current position because I think the asset and macro story are real. But I also think many long-term holders have spent years emotionally locked into waiting for “the moment” while life keeps moving. That’s changed my thinking a lot lately. Conviction still matters, but going forward I think I’ll be much more focused on movement, execution and taking profits when the market finally gives them instead of endlessly waiting for perfection
0 · Reply
Latest News on AKBA
Akebia Therapeutics Earnings Call Transcript: Q1 2026

May 7, 2026, 8:00 AM EDT - 6 days ago

Akebia Therapeutics Earnings Call Transcript: Q1 2026


Akebia doses first participants in AKB-9090 trial

2026-04-13T12:52:17.000Z - 4 weeks ago

Akebia doses first participants in AKB-9090 trial


Akebia Therapeutics Transcript: R&D Day 2026

Apr 2, 2026, 10:00 AM EDT - 5 weeks ago

Akebia Therapeutics Transcript: R&D Day 2026


Akebia Therapeutics Earnings Call Transcript: Q4 2025

Feb 26, 2026, 8:00 AM EST - 2 months ago

Akebia Therapeutics Earnings Call Transcript: Q4 2025


Akebia price target lowered to $4 from $5 at BTIG

2026-02-25T12:25:29.000Z - 2 months ago

Akebia price target lowered to $4 from $5 at BTIG


Akebia price target lowered to $4 from $6 at Piper Sandler

2026-02-06T11:56:25.000Z - 3 months ago

Akebia price target lowered to $4 from $6 at Piper Sandler


Akebia announces corporate updates, 2026 pipeline outlook

2026-01-12T13:52:21.000Z - 4 months ago

Akebia announces corporate updates, 2026 pipeline outlook


Q32 Bio sells complement inhibitor ADX-097 to Akebia

2025-12-01T12:05:21.000Z - 5 months ago

Q32 Bio sells complement inhibitor ADX-097 to Akebia

QTTB


Akebia Announces Establishment of Rare Kidney Disease Pipeline

Dec 1, 2025, 7:00 AM EST - 5 months ago

Akebia Announces Establishment of Rare Kidney Disease Pipeline


Q32 Bio Sells Complement Inhibitor ADX-097

Dec 1, 2025, 7:00 AM EST - 5 months ago

Q32 Bio Sells Complement Inhibitor ADX-097

QTTB


Akebia Therapeutics Earnings Call Transcript: Q3 2025

Nov 10, 2025, 8:00 AM EST - 6 months ago

Akebia Therapeutics Earnings Call Transcript: Q3 2025


Akebia Therapeutics to Present at Upcoming Investor Conferences

Nov 4, 2025, 8:00 AM EST - 6 months ago

Akebia Therapeutics to Present at Upcoming Investor Conferences


Akebia price target lowered to $6 from $8 at H.C. Wainwright

2025-10-30T10:11:16.000Z - 6 months ago

Akebia price target lowered to $6 from $8 at H.C. Wainwright


Akebia Therapeutics Earnings Call Transcript: Q2 2025

Aug 7, 2025, 8:00 AM EDT - 9 months ago

Akebia Therapeutics Earnings Call Transcript: Q2 2025


Akebia assumed with a Buy at H.C. Wainwright

2025-06-04T10:15:38.000Z - 1 year ago

Akebia assumed with a Buy at H.C. Wainwright


Akebia Therapeutics Earnings Call Transcript: Q1 2025

May 8, 2025, 8:00 AM EDT - 1 year ago

Akebia Therapeutics Earnings Call Transcript: Q1 2025


Akebia Therapeutics Earnings Call Transcript: Q4 2024

Mar 13, 2025, 8:00 AM EDT - 1 year ago

Akebia Therapeutics Earnings Call Transcript: Q4 2024


Akebia Therapeutics Earnings Call Transcript: Q3 2024

Nov 7, 2024, 8:00 AM EST - 1 year ago

Akebia Therapeutics Earnings Call Transcript: Q3 2024


GREENJMB81
GREENJMB81 May. 13 at 6:16 PM
0 · Reply
FullTrust
FullTrust May. 13 at 6:08 PM
$AKBA i know your birthday you sent me gift got lost in the mail 🎁 I’ll cut you some slack John
1 · Reply
Coach_B1067
Coach_B1067 May. 13 at 5:52 PM
$AKBA I guess those green bars at the bottom of the chart do not mean anything....smh
1 · Reply
MB76
MB76 May. 13 at 5:51 PM
$AKBA This👇clown thinks any of us “actual” investors in AKBA give a sh*t what he thinks or posts!
1 · Reply
Love_To_Learn
Love_To_Learn May. 13 at 5:47 PM
$AKBA JOHN ILL NEED A FAVOUR SIR * MESSAGING U NOW OFF TOPI NEED U TO DO THIS FOR ME *
0 · Reply
Dipwhits
Dipwhits May. 13 at 5:01 PM
$AKBA As I think back... During my years as a financial analyst and advisor, I would often ask clients a simple question: “What is your most valuable asset?” Almost every answer was material. Money. Homes. Businesses. Portfolios. Very few ever answered: their health or their time. And yet without either of those, none of the material things are even possible. The older I get, the more I realize the market can quietly consume both if you let it. Not just money, but years of your life through stress, waiting, chasing and attachment. Success still matters to me. Ambition still matters. But I think wisdom is learning the difference between building a life and spending your life endlessly waiting for one position, one moment or one number to finally make you feel complete.
2 · Reply
Coach_B1067
Coach_B1067 May. 13 at 5:00 PM
$AKBA No price movement since 10:40?....Seems 'sus'
0 · Reply
The4ccountant
The4ccountant May. 13 at 4:55 PM
$AKBA Nevermind, don’t want it anymore. 💩
0 · Reply
DollaDollaPils
DollaDollaPils May. 13 at 4:32 PM
$AKBA will still be useful for a tax harvest later in the year. Prove me wrong JB and crew, I’d be very happy to be wrong.
0 · Reply
Dipwhits
Dipwhits May. 13 at 4:27 PM
$AKBA One thing this journey has taught me is the market can quietly consume more than money if you let it. It can consume time. And at some point you realize time is the more finite asset. I still believe in the long-term potential here and I’m committed to my current position because I think the asset and macro story are real. But I also think many long-term holders have spent years emotionally locked into waiting for “the moment” while life keeps moving. That’s changed my thinking a lot lately. Conviction still matters, but going forward I think I’ll be much more focused on movement, execution and taking profits when the market finally gives them instead of endlessly waiting for perfection
0 · Reply
Obviate
Obviate May. 13 at 4:13 PM
$AKBA Regarding KCAPA. Q: 'How does KCAPA sponsorship look in this regard?' (I asked AI how KCAPA sponsorship looks regarding KCAPA... this is a follow-on question) "2. Powerful Committee Jurisdiction The identity of KCAPA's sponsors is vastly more important than the absolute number of people signed onto it. The Ways and Means Power: Both Representatives Miller and Sewell sit on the immensely powerful House Committee on Ways and Means, which directly handles Medicare and Social Security legislation. The Advantage: Having original sponsors who are active, influential members of the committee holding jurisdiction over the bill maximizes the odds of it being scheduled for a markup. They do not need 200 cosponsors to get the Committee Chair’s attention—they already have a seat at the table." -AI We have a seat at the table.
3 · Reply
Chamberlain12
Chamberlain12 May. 13 at 3:11 PM
$AKBA THX! At this point, it is IMPORTANT not to get DELUSIONAL We have t oKEEP CEO JB RESPONSIBLE for HIS MULTIPLE F A I L !!!
1 · Reply
skagnetti13
skagnetti13 May. 13 at 3:01 PM
$AKBA Credently
1 · Reply
DonnyDonowitz
DonnyDonowitz May. 13 at 3:00 PM
$AKBA just remember, back then, we thought they wouldn't use all the shares, too....
2 · Reply
Mr_Pithy
Mr_Pithy May. 13 at 2:50 PM
$AKBA Fintel - Jane Street Group 1,456,674 shares, 110.63% increase; Citigroup 2,854,586 shares, 17.17% increase. May 11/12, 2026. Good luck ☘️ to all honest investors.
1 · Reply
DonnyDonowitz
DonnyDonowitz May. 13 at 2:44 PM
1 · Reply
Chamberlain12
Chamberlain12 May. 13 at 1:33 PM
$AKBA Ultimately Magic_Money blocked me cause he wants to stay in his delusional universe...
1 · Reply
KarlDieGlatze
KarlDieGlatze May. 13 at 1:29 PM
$AKBA State Street REDUCES AKBA STAKE by a little more than 15 percent showing less confidence in Johnny Boy. Now 4.3 percent of company outstanding shares. https://archive.fast-edgar.com/20260512/AT226222Z22XG2C222252MY2TAVE7Z222282/
1 · Reply
FoundingFathers
FoundingFathers May. 13 at 1:09 PM
$AKBA New cosponsor for KCAPA. Need this to continue! .R.6214 - Kidney Care Access Protection Act (119th Congress) Sponsor: Rep. Miller, Carol D. [R-WV-1] (Introduced 11/20/2025) Has changes in: Cosponsors (1 new, 11 total) Cosponsor: 05/12/2026: Rep. Panetta, Jimmy [D-CA-19]
1 · Reply
Chamberlain12
Chamberlain12 May. 13 at 1:07 PM
$AKBA MM, I am not short but it is a SHAME U become more and more delusional and sound like amateur JB himself. Sorry but not sorry. All you quote should have happened more than TWO YEARS AGO after approval. Check REALITY
2 · Reply
DonnyDonowitz
DonnyDonowitz May. 13 at 12:59 PM
0 · Reply
Akba_BO
Akba_BO May. 13 at 11:54 AM
$AKBA CEO Butler if executive comp and increase in AS passes. Be smart. VOTE NO!
0 · Reply